{
    "Trade/Device Name(s)": [
        "LZI Oxycodone III Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K202007",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120763"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "September 17, 2020",
    "Summary Letter Received Date": "July 21, 2020",
    "Submission Date": "July 17, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone",
        "Oxymorphone",
        "Noroxycodone",
        "Noroxymorphone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU480 automated clinical analyzer",
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay",
        "Spectrophotometric detection"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Oxycodone III Enzyme Immunoassay for qualitative and semi-quantitative determination of oxycodone in human urine using enzyme immunoassay on automated clinical chemistry analyzers.",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of oxycodone in human urine at cutoff values of 100 ng/mL and 300 ng/mL, for prescription use with automated clinical chemistry analyzers; provides preliminary analytical result requiring confirmation by alternative chemical methods.",
    "fda_folder": "Toxicology"
}